Key Points
- Vaxcyte COO Jim Wassil sold 3,477 shares at an average price of $61.07, generating $212,340.39. The transaction was conducted to cover tax withholding tied to vested equity awards and reduced his holdings by 2.19%.
- Vaxcyte shares opened at $61.58, near their 12-month high of $65.00, giving the company a market capitalization of approximately $9.16 billion. The company reported a quarterly loss of $1.97 per share, beating analyst expectations of a $2.06 loss.
- Analysts assign Vaxcyte an overall “Moderate Buy” rating, with an average price target of $86.00; five analysts rate the stock Buy, two Hold, and one Sell. Institutional investors own 96.78% of the company’s shares.
Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) COO Jim Wassil sold 3,477 shares of Vaxcyte stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $61.07, for a total transaction of $212,340.39. Following the completion of the sale, the chief operating officer owned 155,041 shares of the company's stock, valued at $9,468,353.87. This trade represents a 2.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Jim Wassil also recently made the following trade(s):
- On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $53.86, for a total transaction of $121,185.00.
- On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.33, for a total transaction of $126,742.50.
Vaxcyte Trading Up 1.3%
Shares of PCVX opened at $61.58 on Thursday. Vaxcyte, Inc. has a 12 month low of $30.81 and a 12 month high of $65.00. The firm's 50 day moving average is $57.98 and its 200-day moving average is $56.12. The stock has a market capitalization of $9.16 billion, a PE ratio of -8.07 and a beta of 1.22.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same period in the prior year, the firm earned ($1.22) earnings per share. Equities research analysts predict that Vaxcyte, Inc. will post -7.6 earnings per share for the current fiscal year.
Institutional Trading of Vaxcyte
Large investors have recently made changes to their positions in the company. NEXTBio Capital Management LP bought a new stake in Vaxcyte during the fourth quarter worth $4,406,000. Norges Bank bought a new position in shares of Vaxcyte in the 4th quarter valued at $56,703,000. Seven Fleet Capital Management LP increased its stake in shares of Vaxcyte by 406.4% in the 1st quarter. Seven Fleet Capital Management LP now owns 128,450 shares of the company's stock valued at $7,464,000 after purchasing an additional 103,085 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Vaxcyte by 73.4% during the 1st quarter. Bank of America Corp DE now owns 1,216,843 shares of the company's stock worth $70,711,000 after buying an additional 515,209 shares in the last quarter. Finally, Candriam S.C.A. acquired a new position in shares of Vaxcyte during the 1st quarter worth $18,306,000. Institutional investors and hedge funds own 96.78% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on PCVX shares. Zacks Research upgraded Vaxcyte from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Vaxcyte in a research report on Monday, July 6th. Finally, Wall Street Zen raised Vaxcyte from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 8th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $86.00.
Read Our Latest Report on PCVX
About Vaxcyte
(
Get Free Report)
Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company's platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.
Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
